- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05250505
Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
Pilot Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, non-randomized, open-label, single-center, pilot study in subjects with normal pressure hydrocephalus for whom a traditional CSF shunt implant is indicated.
Up to 30 subjects will receive the eShunt Implant at one investigational site. Subjects will return for five follow-up visits in the first year and then continue to attend visits every six months for five years post-implantation.
The study objectives are to demonstrate safety of the eShunt Procedure, as well as demonstrate safety and efficacy of the eShunt Implant in a small sample of patients.
Subjects will be followed long-term; primary analysis results will be used to support additional studies.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: DJ Cass
- Email: djcass@cerevasc.com
Study Contact Backup
- Name: Ona Whelove
- Phone Number: 4155152885
- Email: clinicaltrials@cerevasc.com
Study Locations
-
-
Ciudad A. De Buenos Aires
-
Buenos Aires, Ciudad A. De Buenos Aires, Argentina, C1426B
- Recruiting
- Clínica La Sagrada Familia
-
Contact:
- Carlos Toranzo
- Email: ctoranzo@lylyk.com.ar
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients 65-85 years old and traditional CSF shunt placement is indicated based upon a diagnostic NPH evaluation
- Patient is able and willing to provide written informed consent
- History or evidence of gait impairment duration ≥6 months
Clinical presentation consistent with NPH including 2 or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with:
- Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans Index >0.3) and the absence of severe hippocampal atrophy
- Pre-procedure spinal tap test with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%
- CSF opening pressure ≥10 cmH2O
- Baseline cognitive evaluation assessed by Montreal Cognitive Assessment (MoCA) test score ≥12
- Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC
- Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC
Exclusion Criteria:
- Unable to walk 10 meters (33 feet) with or without an assistive device
- Conditions impairing gait that are considered to be unrelated to hydrocephalus
- Signs or symptoms of obstructive hydrocephalus
- Active systemic infection or infection detected in CSF
- Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
- Hypersensitivity or contraindication to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available
- Occlusion or stenosis of the internal jugular vein
- Venous distension in the neck on physical exam
- Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram
- History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency
- Stroke or transient ischemic attack within 180 days of eShunt Procedure
- Presence of a deep vein thrombosis superior to the popliteal vein
- International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds)
- Presence of a posterior fossa tumor or mass
- Life expectancy < 1 year
- Currently participating in another investigational drug or device trial that could conflict with study data collection or follow-up
- Other medical illnesses that may cause the patient to be non-compliant with the protocol or confound data interpretation
- Pregnant or planning to become pregnant
- Unwilling or unable to comply with follow-up requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
The Treatment Arm receives the eShunt Implant.
|
The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device and/or procedure-related serious adverse events (SAEs)
Time Frame: 90 days following eShunt Implant deployment
|
Rate of occurrence of device and/or procedure-related serious adverse events (SAEs)
|
90 days following eShunt Implant deployment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with abnormal MRI findings
Time Frame: 90 days following eShunt Implant deployment
|
Number of participants with abnormal MRI findings and descriptive summaries of findings
|
90 days following eShunt Implant deployment
|
Number of participants with abnormal CT findings
Time Frame: 90 days following eShunt Implant deployment
|
Number of participants with abnormal CT findings and descriptive summaries of findings
|
90 days following eShunt Implant deployment
|
Number of participants with clinically significant abnormal complete blood count (CBC) results
Time Frame: 90, 180 and 365 days following eShunt Implant deployment
|
Number of participants with clinically significant abnormal results and descriptive summaries of CBC results
|
90, 180 and 365 days following eShunt Implant deployment
|
Number of participants with clinically significant abnormal blood chemistry results
Time Frame: 90, 180 and 365 days following eShunt Implant deployment
|
Number of participants with clinically significant abnormal findings and descriptive summaries of blood chemistry results
|
90, 180 and 365 days following eShunt Implant deployment
|
Number of participants with clinically significant abnormal neurological exam findings
Time Frame: 90, 180 and 365 days following eShunt Implant deployment and at study completion
|
Number of participants with clinically significant abnormal findings and descriptive summaries of neurological exam finding
|
90, 180 and 365 days following eShunt Implant deployment and at study completion
|
Number of participants with adverse events
Time Frame: 90, 180 and 365 days following eShunt Implant deployment and at study completion
|
Tabulation of all adverse events
|
90, 180 and 365 days following eShunt Implant deployment and at study completion
|
Change in gait compared to baseline
Time Frame: 90, 180 and 365 days following eShunt Implant deployment
|
Change in gait compared to baseline as measured by the duration in seconds of the Timed Up and Go Test (shorter durations indicate improvement (increased mobility))
|
90, 180 and 365 days following eShunt Implant deployment
|
Change in cognitive ability compared to baseline
Time Frame: 90, 180 and 365 days following eShunt Implant deployment
|
Change in cognitive ability compared to baseline as measured by Montreal Cognitive Assessment (MoCA) scores (scores range from 0-30; higher scores indicate improvement (less cognitive disability))
|
90, 180 and 365 days following eShunt Implant deployment
|
Change in urinary symptoms compared to baseline
Time Frame: 90, 180 and 365 days following eShunt Implant deployment
|
Change in urinary symptoms compared to baseline as measured by the Neurogenic Bladder Symptom Score (NBSS) (scores range from 0-28; lower scores indicate improvement (fewer symptoms))
|
90, 180 and 365 days following eShunt Implant deployment
|
Change in Modified Rankin Scale compared to baseline
Time Frame: 90, 180 and 365 days following eShunt Implant deployment
|
Change in degree of disability compared to baseline as measured by Modified Rankin Scale (mRS) scores (scores range from 0-6; lower scores indicate improvement (less disability))
|
90, 180 and 365 days following eShunt Implant deployment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pedro Lylyk, MD, Clínica La Sagrada Familia
Publications and helpful links
General Publications
- Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum In: J Am Geriatr Soc. 2019 Sep;67(9):1991.
- Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9.
- Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5):495-9. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3.
- Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014 Aug;192(2):452-7. doi: 10.1016/j.juro.2014.01.027. Epub 2014 Feb 8.
- Welk B, Lenherr S, Elliott S, Stoffel J, Gomes CM, de Bessa J, Cintra LKL, Myers JB; Neurogenic Bladder Research Group. The creation and validation of a short form of the Neurogenic Bladder Symptom Score. Neurourol Urodyn. 2020 Apr;39(4):1162-1169. doi: 10.1002/nau.24336. Epub 2020 Mar 20.
- Serrano CM, Sorbara M, Minond A, Finlay JB, Arizaga RL, Iturry M, Martinez P, Heinemann G, Gagliardi C, Serra A, Magliano FC, Yacovino D, Rojas MMEY, Ruiz AS, Graviotto HG. Validation of the Argentine version of the Montreal Cognitive Assessment Test (MOCA): A screening tool for Mild Cognitive Impairment and Mild Dementia in Elderly. Dement Neuropsychol. 2020 Apr-Jun;14(2):145-152. doi: 10.1590/1980-57642020dn14-020007.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-0012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hydrocephalus
-
University of Kansas Medical CenterNot yet recruitingLow Pressure Hydrocephalus
-
Umeå UniversityCompletedIdiopathic Normal Pressure Hydrocephalus
-
Uppsala University HospitalUppsala University; Swedish Society for Medical ResearchRecruitingIdiopathic Normal Pressure Hydrocephalus (INPH)Sweden
-
Johns Hopkins UniversityUniversity of Utah; Integra LifeSciences CorporationCompletedIdiopathic Normal Pressure Hydrocephalus (INPH)United States, Canada, Sweden
-
Military University Hospital, PragueRecruitingNormal Pressure HydrocephalusCzechia
-
University Hospital, ToulouseCompleted
-
Rabin Medical CenterUnknown
-
Mayo ClinicTerminatedNormal Pressure Hydrocephalus PatientsUnited States
-
Umeå UniversityCompleted
-
Dokuz Eylul UniversityRecruitingNPH (Normal Pressure Hydrocephalus)Turkey
Clinical Trials on eShunt Implant
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...TerminatedPilot Study to Evaluate the CereVasc® eShunt® System in the Treatment of Communicating HydrocephalusHydrocephalus | Hydrocephalus, CommunicatingUnited States
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...RecruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLCRecruitingHydrocephalus | Hydrocephalus, Normal PressureUnited States
-
Aula Dental AvanzadaRecruiting
-
University of Sao PauloCompletedCataract | AstigmatismBrazil
-
Aula Dental AvanzadaCompleted
-
Mentor Worldwide, LLCWithdrawnAugmentation | Augmentation Revision | General Breast Enlargement | Post-lactational Involution | AsymmetryUnited States
-
ZimVieCompletedPartial Edentulism | Tooth DiseaseUnited States
-
Ideal Implant IncorporatedCompletedBreast ImplantsUnited States
-
University of BernNot yet recruitingComplications | Patient Reported Outcome Measures | Cost-Benefit Analysis | Cost-effectiveness | Esthetic Zone | Single Tooth Dental Implant | Single Tooth Lost | Accuracy of Dental Implants | Dimensional Changes | Implant Survival and Success | Frequency of Treatment ProtocolSwitzerland